Pfenex Announces Positive Anthrax Vaccine Study Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 flat as chipmakers fall and bank earnings roll in
- Oil prices mixed as US-Russia diesel deal hopes offset Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- CoreWeave stock drops on insider selling notice
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Sysco calls on Teamsters to end LA strike after economic deal reached
Pfenex (PFNX) Tops Q2 EPS by 4c
August 8, 2016 7:33 AM EDTPfenex (NYSE: PFNX) reported Q2 EPS of ($0.43), $0.04 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $2.55 million.
For earnings history and earnings-related data on Pfenex (PFNX) click here.
... More


